Prostacyclin (PGI2) Role and Function in Pulmonary Arterial Hypertension (PAH)
Автор: PAH Initiative
Загружено: 2024-11-12
Просмотров: 1089
In this video for healthcare professionals treating patients with Pulmonary Arterial Hypertension (WHO Group 1 PAH), you will learn how PAH negatively impacts the small pulmonary arteries ultimately leading to reduced cardiac output and right heart failure. These pathologic changes are associated with prostacyclin deficiency and are linked to PAH disease severity and progression. Prostacyclin replacement therapies have been shown to improve hemodynamic parameters and right heart function, including cardiac output and pulmonary vascular resistance (PVR), improve functional outcomes, and delay disease progression. Prostacyclin replacement therapy is available in oral, inhaled and parenteral routes of administration enabling its use at all stages of PAH disease.
Contents of this video:
00:00 – PAH Pathophysiology
01:52 – The Role of Prostacyclin in PAH
02:45 – The Prostacyclin Pathway and Replacement Therapy
04:48 – Treatment Considerations
Доступные форматы для скачивания:
Скачать видео mp4
-
Информация по загрузке:
